Valerie Curran
Professor of Psychopharmacology
Data updated
Research Footprint
Valerie Curran appears in 13 tracked papers (2013–2022), most studied alongside MDMA, Psilocybin and Ketamine, across Depressive Disorders, Substance Use Disorders (SUD) and Neuroimaging & Brain Measures.
Most-cited paper: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (1520 citations).
Frequent co-authors: David Nutt, Robin Carhart-Harris and Matthew Bolstridge.
Publication Landscape
How the 13 papers Blossom tracks for Valerie Curran line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Valerie Curran's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 13 of 13 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Valerie Curran publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Valerie Curran publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Valerie Curran is a UK-based psychopharmacologist and neuroscientist notable for rigorous experimental and clinical research on the behavioural, cognitive and neural effects of MDMA, ketamine and classical psychedelics. Her work spans naturalistic and experimental studies of ecstasy/MDMA (including effects on cooperative behaviour, trustworthiness and neurocognitive function), mechanistic and clinical investigations of ketamine (including modulation of reward processing and trials of adjunctive ketamine with relapse-prevention psychological therapy for alcohol use disorder), and multimodal neuroimaging studies characterising the neural correlates of the LSD experience and its effects on emotional responses to music.
Beyond primary research, Curran has contributed influential reviews and harm-reduction literature (for example, on ketamine-related urological harms and the broader harms associated with psychoactive substances) and has been active in methodological and policy discussions around conducting and reporting psychedelic research. Her interdisciplinary portfolio integrates psychopharmacology, neuroimaging, clinical trial methods and public-health perspectives, positioning her as a key figure in translating basic experimental findings into therapeutic and regulatory contexts.
Key Impact
A leading UK psychopharmacologist whose experimental and clinical work on MDMA (ecstasy), ketamine and classical psychedelics has shaped understanding of cognitive, social and therapeutic effects of these compounds and informed policy on drug harms and research practice.
Collaboration Network
31 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Valerie Curran's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Valerie Curran is associated with.